Aerie pharmaceuticals announces acceptance of its investigational new drug application for ar-15512 eye drop for dry eye disease

Aerie pharmaceuticals announces acceptance of its investigational new drug application for ar-15512 (trpm8 agonist) eye drop for dry eye disease.aerie pharmaceuticals - expects to initiate a phase 2b clinical study in q4 of 2020 for ar-15512.aerie pharmaceuticals - expect to begin phase 2b clinical study, which will be powered as phase 3, later this year, with topline readout in q3 2021.
AERI Ratings Summary
AERI Quant Ranking